Formulation and Evaluation of Imeglimin Hydrochloride Immediate Release Tablet
Kamlesh Singh Bora1, Archana Rautela2, Reetu Papola3, Praveen Kumar Ashok4
1Kamlesh Singh Bora Department of Pharmaceutics, Gyani Inder Singh Institute of Professional Studies, Dehradun, Uttarakhand, India.
2Archana Rautela, Department of Pharmaceutics, Gyani Inder Singh Institute of Professional Studies, Dehradun, Uttarakhand, India.
3Reetu Papola, Department of Pharmaceutics, Gyani Inder Singh Institute of Professional Studies, Dehradun, Uttarakhand, India.
4Praveen Kumar Ashok, Department of Pharmaceutics, Gyani Inder Singh Institute of Professional Studies, Dehradun, Uttarakhand, India.
Manuscript received on 09 March 2023 | Revised Manuscript received on 18 March 2023 | Manuscript Accepted on 15 April 2023 | Manuscript published on 30 April 2023 | PP: 37-47 | Volume-3 Issue-3, April 2023 | Retrieval Number: 100.1/ijapsr.F4027103623 | DOI: 10.54105/ijapsr.F4027.03030423
Open Access | Editorial and Publishing Policies | Cite | Indexing and Abstracting
© The Authors. Published by Lattice Science Publication (LSP). This is an open-access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Abstract: Imeglimin hydrochloride, an oral drug that oversees type 2 diabetes, brings down blood glucose levels. Among other impacts, it also supports mitochondrial DNA and movement while reducing the production of reactive oxygen species (ROS). Imeglimin tablets with a quick delivery recipe are presently being created and tried frequently. Tests were conducted using super-disintegrants, such as Croscarmellose sodium, and the amount of PVPK-30 was adjusted to reduce the disintegration time further. Microcrystalline. The diluent in the definition preliminaries was cellulose, the folio was polyvinylpyrrolidone (K30), and the Glidant was colloidal silicon dioxide. Using the USP Device II (Paddle) at a temperature of 37°C ± 0.5°C and a speed of 50 rpm, the in vitro drug release was studied. Hydrochloric acid, 0.1 N, was utilised as the dissolving agent. For preliminaries F1 and F6, the level of the drug administered at different times was determined using UV technology. The review’s findings revealed that Preliminary F6 provided the best detailing. Every estimation was within the permitted range specified by the Pharmacopoeial Details. The actual properties of different tablets, including hardness, thickness, weight variation, friability, percentage drug content, and in vitro drug release, were scrutinised.
Keywords: Type 2 diabetes, Wet granulation, In vitro dissolution, Disintegration, and Pre-formulation, Imeglimin hydrochloride.
Scope of the Article: Pharmaceutical Technology